Af­ter 'grow­ing up' last year, Mod­er­na warns of loss­es and charts path back to prof­its: #JPM24

Mod­er­na’s pre­sen­ta­tion on Mon­day at #JPM24 sig­naled a marked shift in tone from one of biotech’s Covid-19 su­per­stars.

With the pan­dem­ic in the rearview mir­ror, Mod­er­na large­ly stayed away from dis­cussing ear­ly-stage re­search and in­stead em­pha­sized a swath of piv­otal da­ta read­outs from on­go­ing Phase III pro­grams and po­ten­tial com­mer­cial launch­es of four vac­cines over the next two years.

The late-stage fo­cus comes as Covid-19 vac­cine sales have slowed down sig­nif­i­cant­ly and in­vestors search for what can make up for those loss­es. Noth­ing crys­tal­lized the tran­si­tion more than the man who gave Mod­er­na’s keynote pre­sen­ta­tion: James Mock, their chief fi­nan­cial of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER